关于董事会收到股东临时提案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 北海国发川山生物股份有限公司（以下简称"公司"）于2025年12月1日召开了第十一届董事会第二十次 会议，审议通过了《关于召开2025年第三次临时股东大会的议案》，公司董事会定于2025年12月18日召 集召开公司2025年第三次临时股东大会，具体内容详见公司2025年12月2日在《上海证券报》《中国证 券报》《证券时报》《证券日报》和上海证券交易所网站（http://www.sse.com.cn）披露的《第十一届 董事会第二十次会议决议公告》（临2025-046）、《关于召开公司2025年第三次临时股东大会的通知》 （临2025-051）。 2025年12月6日，公司董事会收到了持有公司7.57%股份的股东朱蓉娟提交的临时提案（以下简称"临时 提案一"）；2025年12月7日，公司董事会收到了合计持有公司3.15%股份的股东何杏桃、梁荣富、郑智 奕、梁静娴、梁太嫦书面提交的临时提案（以下简称"临时提案二"）。公司董事会按照《中华人民共和 国公司 ...

Core Insights - The animal health sector experienced a rise of 1.81% on December 8, with BioShares leading the gains [1] - The Shanghai Composite Index closed at 3924.08, up 0.54%, while the Shenzhen Component Index closed at 13329.99, up 1.39% [1] Stock Performance - BioShares (600201) closed at 14.39, with a significant increase of 7.39% and a trading volume of 717,500 shares, amounting to a turnover of 1.014 billion yuan [1] - Other notable stocks included: - Zhongmu Co. (600195) at 8.09, up 1.25% [1] - Deyu Bio (920970) at 7.88, up 0.90% [1] - Yongshun Bio (920729) at 8.85, up 0.80% [1] - Ruipu Bio (300119) at 19.37, up 0.73% [1] Capital Flow Analysis - The animal health sector saw a net outflow of 27.984 million yuan from institutional investors, while retail investors contributed a net inflow of 4.809 million yuan [2] - The main capital flow for BioShares (600201) showed a net inflow of 26.5384 million yuan from institutional investors, despite a net outflow of 35.9123 million yuan from retail investors [3] - Other stocks like *ST Lvkang (002868) and Huisheng Bio (300871) also experienced varied capital flows, with institutional and retail investors showing different trends [3]

Core Viewpoint - The company, Liaoning Chengda Biological Co., Ltd., is convening its second extraordinary general meeting of shareholders in 2025 to discuss adjustments to its fundraising projects and internal investment structure, including the termination of certain research projects and the allocation of funds to new initiatives [1][18]. Meeting Details - The second extraordinary general meeting of shareholders will be held on December 23, 2025, at 9:30 AM in Shenyang, Liaoning Province [4]. - The meeting will utilize a combination of on-site and online voting methods, with specific time slots for voting [2][6]. Fundraising Project Adjustments - The company plans to optimize the internal investment structure of its "Human Vaccine Research Project" by terminating five research sub-projects and reallocating unused funds to other ongoing and new sub-projects, specifically the "High-Value Pneumococcal Polysaccharide Conjugate Vaccine" and "High-Dose Influenza Virus Split Vaccine" [19][30]. - A total of 100 million yuan will be specifically allocated to increase capital in its wholly-owned subsidiary, Chengda Biological (Benxi) Co., Ltd., to support the implementation of the "High-Dose Influenza Virus Split Vaccine" [19][43]. Project Timeline Extensions - The fundraising usage period for the "Human Vaccine Research Project" and "Biotechnology Product R&D Production Base Project" has been extended to December 2028 to adapt to global macroeconomic changes and industry trends [20][46]. - The adjustments made will not affect the total planned investment amount for the "Human Vaccine Research Project" [41]. Financial Management and Compliance - The company has established a special account for the management of the raised funds, ensuring that all funds are used specifically for the designated projects [45]. - The adjustments and extensions have been approved by the company's board and will be submitted for shareholder approval at the upcoming meeting [25][46].

证券之星消息，12月5日动物保健板块较上一交易日上涨1.45%，生物股份领涨。当日上证指数报收于 3902.81，上涨0.7%。深证成指报收于13147.68，上涨1.08%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002868 | *ST绿康 | 36.64 | -0.57% | 3.37万 | 1.22亿 | | 300119 | 瑞普生物 | 19.23 | -0.21% | 4.17万 | 8014.54万 | | 920275 | 驱动力 | 8.93 | 0.00% | 2.17万 | 1895.31万 | | 688526 | 科前生物 | 15.55 | 0.32% | 1.20万 | 1862.15万 | | 603566 | 普莱柯 | 13.08 | 0.46% | 2.52万 | 3283.78万 | | 002141 | 贤丰控股 | 3.94 | 0.51% | 21.89万 | 8580.68万 | | 688098 | 申联生 ...

■ 一、董事长辞任的基本情况 北海国发川山生物股份有限公司（以下简称"公司"）董事会于2025年12月2日收到公司董事长姜烨先生 的书面辞职报告，其因个人原因申请辞去公司第十一届董事会董事、董事长及董事会战略委员会主任委 员、董事会提名委员会委员的职务，同时不再担任公司法定代表人。辞任后，姜烨先生不再担任公司及 控股子公司任何职务。根据相关规定，其辞职申请自公司收到通知之日起生效。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 特此公告。 北海国发川山生物股份有限公司 董 事 会 2025年12月4日 截至2025年12月2日，姜烨先生持有公司4,804,900股股份（占公司总股本的比例为0.92%），其不存在 应当履行而未履行的承诺事项，其持有的公司股份将严格按照相关监管规定进行后续管理。 根据《公司法》和《公司章程》的相关规定，姜烨先生辞去董事、董事长职务不会导致公司董事会成员 低于法定最低人数，不会影响公司董事会的正常运行。公司将根据相关规定，按照法定程序尽快完成公 司董事补选、新任董事长选举及补选董事会专门委员会委员 ...

Group 1 - The average price of live pigs in China is 11.63 yuan/kg as of November 29, showing a decline of 1.11% compared to the previous weekend, with the industry facing a loss of 111 yuan per head for nine consecutive weeks [1] - The price of weaned piglets at 7 kg is 209 yuan per head, with an average loss of approximately 81 yuan per head for exported piglets this week [1] - The average slaughter weight this week is 129.22 kg, with a slight increase of 0.41 kg week-on-week, while the average slaughter weight for smallholders is at a high of 145.17 kg [1] Group 2 - The demand side shows an increase in daily slaughter volume by 3.39% week-on-week, driven by northern slaughterhouses responding to low pig prices and the onset of seasonal consumption in southern markets [1] - There are sporadic outbreaks of pig diseases in certain regions due to cooler weather, with the proportion of pigs under 90 kg in total slaughter increasing to 4.83%, up by 0.34% from last week [1] - The agricultural team emphasizes the importance of monitoring the pig sector's capacity reduction due to production cuts, losses in farming, and disease interference, suggesting that capacity may continue to decrease [1] Group 3 - As of December 3, 2025, the CSI Livestock Breeding Index shows significant gains for several stocks, including Luoniushan up by 9.98% and Yike Foods up by 3.36% [2] - The Livestock ETF closely tracks the CSI Livestock Breeding Index, which includes companies involved in feed, veterinary drugs, and livestock farming [2] - The top ten weighted stocks in the CSI Livestock Breeding Index account for 65.6% of the index, with major companies like Muyuan Foods and Wens Foodstuffs leading the list [2]

Core Viewpoint - The Inner Mongolia Federation of Industry and Commerce has played a crucial role in supporting the development of private enterprises, celebrating its 70th anniversary while emphasizing its commitment to serving the private economy and fostering innovation [1][13][28]. Group 1: Company Development and Achievements - Jin Yu Biotechnology Co., Ltd. has emerged as a leader in the biological industry, driven by technological innovation and contributing significantly to the development of the region's biological sector [4][19]. - The company overcame initial challenges such as technological blockades and funding shortages, achieving significant breakthroughs in vaccine technology, including the development of a large-scale cell suspension culture technology and a purification process that shortened the gap with international standards by 20 years [5][20]. - Jin Yu has invested 2.5 billion yuan in building an international technology industrial park, establishing the world's first intelligent manufacturing plant for animal vaccines, and creating the first mRNA vaccine production facility for animals [7][22]. Group 2: Technological Innovation and Research - The company has continuously upgraded its vaccine production processes, transitioning from manual cultivation to fully automated systems, and has developed a comprehensive smart epidemic prevention system [8][23]. - Over the past six years, Jin Yu has invested 1.2 billion yuan in research and development, resulting in over 120 invention patents and 27 pioneering technologies, significantly enhancing domestic animal disease prevention capabilities [10][25]. - The establishment of a national animal disease detection big data platform has allowed the company to provide comprehensive services to livestock farms, enhancing customer loyalty and shifting its business model from pure vaccine sales to integrated service offerings [23]. Group 3: Industry Collaboration and Future Directions - Jin Yu has positioned itself as a key player in the biopharmaceutical industry chain in Inner Mongolia, collaborating with various organizations to promote animal health and welfare [25][31]. - The company aims to integrate biotechnology with artificial intelligence to enhance production capabilities and is committed to social responsibility, actively participating in rural revitalization and public welfare initiatives [31]. - The successful hosting of the first International Animal Vaccine Innovation Conference highlights Jin Yu's role in fostering collaboration and innovation within the industry [27].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688739 证券简称：成大生物 公告编号：2025-056 辽宁成大生物股份有限公司关于以集中竞价交易方式回购公司股份的进展公告 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7号一一回购股份》等相关 规定，公司在回购股份期间，应当在每个月的前3个交易日内披露截至上月末的回购进展情况。公司回 购股份的进展情况如下： 2025年11月，公司未实施股份回购。截至2025年11月30日，公司通过上海证券交易所交易系统以集中竞 价交易方式已累计回购公司股份384,899股，占公司总股本的比例约为0.092%，回购成交的最高价为 29.61元/股，最低价为27.20元/股，已支付的资金总额为人民币10,789,216.56元（不含交易费用和佣 金）。 上述回购股份符合相关法律法规及公司回购股份方案的规定。 三、其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7号一一回购股 份》等相关规定，在回购期限内根据市场情况择机做出回购决策并予以实施，同时根据回购股份事项进 展情况及时履行 ...

Core Viewpoint - The animal health sector experienced a decline of 0.48% on December 1, with *ST Lvkang leading the drop, while the overall market indices showed positive performance with the Shanghai Composite Index rising by 0.65% and the Shenzhen Component Index increasing by 1.25% [1][2]. Market Performance - The closing price of *ST Lvkang was 39.35, reflecting a decrease of 3.41% with a trading volume of 30,400 shares and a transaction value of 122 million yuan [2]. - Other notable stocks in the animal health sector included: - Dayu Biological: Closing price 8.26, up 2.10% [1] - Haili Biological: Closing price 6.86, up 1.03% [1] - Qihua Biological: Closing price 15.85, up 0.51% [1] - Repu Biological: Closing price 19.83, down 0.10% [1][2]. Capital Flow - The animal health sector saw a net outflow of 29.57 million yuan from institutional investors, while retail investors contributed a net inflow of 3.27 million yuan [2][3]. - Specific stock capital flows included: - Jinhai Biological: Net inflow from institutional investors of 3.13 million yuan [3]. - Haili Biological: Net inflow from institutional investors of 2.06 million yuan [3]. - Repu Biological: Net inflow from retail investors of 2.81 million yuan [3].

Core Insights - The avian influenza concept sector experienced a decline of 0.76%, ranking among the top losers in the market, with major stocks like Zhongsheng Pharmaceutical hitting the limit down, while a few stocks like Wens Foodstuff and Weilan Biology saw gains of 1.80% each [1][2] Market Performance - The top-performing concept sectors included Titanium Dioxide with a gain of 4.31%, and Hainan Free Trade Zone with a gain of 3.54%, while the avian influenza sector was among the worst performers [1] - The avian influenza sector saw a net outflow of 784 million yuan, with 18 stocks experiencing net outflows, led by Zhongsheng Pharmaceutical with a net outflow of 684 million yuan [1] Stock Performance - Stocks with significant net outflows included: - Zhongsheng Pharmaceutical: -10.00% with a turnover rate of 18.78% and a net outflow of 683.65 million yuan - Yiling Pharmaceutical: -2.40% with a net outflow of 35.71 million yuan - Lianhuan Pharmaceutical: -1.79% with a net outflow of 25.69 million yuan - Hualan Biological: -6.60% with a net outflow of 18.13 million yuan [1] - Conversely, stocks with net inflows included: - Tiankang Biological: +1.26% with a net inflow of 16.52 million yuan - Shanghai Kaibao: -1.70% with a net inflow of 5.06 million yuan - Jinhai Biological: +0.16% with a net inflow of 3.82 million yuan [2]